SIR 2024
Interventional Oncology
Marios Platon Dimopoulos, MD,MSc
Resident
University Hospital of Patras, Greece
Disclosure information not submitted.
Trifon Spyridonidis, MD, PhD
NUCLEAR MEDICINE DOCTOR
GENERAL UNIVERSITY HOSPITAL OF PATRAS NUCLEAR MEDICINE DEPARTMENT, Greece
Disclosure information not submitted.
Nikos Giannikas, MD, MS
Resident
General University Hospital of Patras, Greece
Disclosure information not submitted.
Ioannis Spyridonidis, MD, PhD
Attending Radiologist
General University Hospital of Patras, Greece
Disclosure information not submitted.
Panagiotis Kitrou, MD, PhD
Asst. Prof. in Interventional Radiology
Patras University Hospital, Greece
Disclosure information not submitted.
George Nistikoulis, MD
Resident
General University Hospital of Patras, Greece
Disclosure information not submitted.
fotis Anagnostopoulos, MD
Interventional Radiology Fellow
2nd Department of Radiology, University General Hospital "ATTIKON" Medical School, National and Kapodistrian University of Athens, Greece
Disclosure information not submitted.
Vasiliki Taki, MD
Resident
General University Hospital of Patras, Greece
Disclosure information not submitted.
Evangelia Christodoulou, MD, MS
Resident
General University Hospital Of Patras, Greece
Disclosure information not submitted.
Michalis Theofanis, MD
Attending Radiologist
General University Hospital of Patras, Greece
Disclosure information not submitted.
Nefeli Chaniotaki, MD, MS
RESIDENT
GENERAL UNIVERSITY HOSPITAL OF PATRAS, Greece
Disclosure information not submitted.
Christos Papageorgiou, MD
Attending
General University Hospital of Patras, Greece
Disclosure information not submitted.
Dimitrios Karnabatidis, MD, PhD, EBIR, FCIRSE
Professor in Interventional Radiology
Interventional Radiology, Patras University Hospital, Greece
Disclosure information not submitted.
Konstantinos Katsanos, MD, PhD, MS
Ass Professor
General University Hospital of Patras, Greece
Disclosure information not submitted.
There were three grade 3 complications (9.0%) and no instance of REILD. Mean tumor dose was 195±163 Gy. After a median follow-up of 10 months, complete response (CR) was observed in 64% (21/33) of the irradiated tumors with an overall disease control rate of 94% (31/33). Median dose was significant higher in CR cases (278±185 Gy) versus stable or partial response ones (137±114 Gy; p=0.0099). Median liver PFS was 7 months. Median patient OS was 11 months.
Conclusion: Y90 ablation has an acceptable safety profile and may achieve high rates of tumor necrosis and local disease control for the treatment of large inoperable liver tumors. Mean tumor absorbed dose plays a significant role in tumor response